Fate Therapeutics ( NASDAQ:FATE ) First Quarter 2024 Results Key Financial Results Net loss: US$48.0m (loss widened by...
Despite Revenue Growth, Losses Widen; Clinical Trials Progress in Autoimmune and Cancer Treatments
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?